Jinfeng Wu

Dr. Jinfeng Wu

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JLJiexiang Lin
Jiexiang Lin
ZYZesong Yang
Zesong Yang
LYLiefu Ye
Liefu Ye
YHYun Hong
Yun Hong
WCWanghai Cai
Wanghai Cai
JWJinfeng Wu
Jinfeng Wu
This study aimed to analyze the infection risk factors for transurethral resection of the prostate (TURP) and establish predictive models to help make personalized treatment plans. Our study was designed one-center and retrospectively enrolled 1169 benign prostatic hyperplasia (BPH) patients. Risk factors were explored for postoperative infection. A TURP-postoperative infection (TURP-PI) model with infection prediction values was created. The improved-TURP-PI (I-TURP-PI) model, including extra new factors (pathogens species), was also built to see whether it could optimize the prediction abilities. At last, we developed a nomogram for better clinical application. Operation time, preoperative indwelling urinary catheter (PIUC), and positive preoperative urine culture were independent risk factors (all P < 0.05). Interestingly, pathogens species in pre-surgery urine (PEnterococcus faecium = 0.014, PPseudomonas aeruginosa = 0.086) were also independent risk factors. Patients with positive Enterococcus faecium (37.50%) were most likely to have postoperative infection. We built two models with AUCTURP-PI = 0.709 (95% CI 0.656–0.763) and AUCI-TURP-PI = 0.705 (95% CI 0.650–0.760). The nomogram could help improve the prediction ability. To our knowledge, our study is the first to use pathogen species in urine before surgery as risk factors for infection prediction after TURP. TURP-PI and I-TURP-PI models have essential roles in predicting patients' postoperative infections and in better postoperative antibiotic decision-making.

17 October 2023 in Gene
Verified
Journal Article
Open access
JWJinfeng Wu
Jinfeng Wu
SZSuqin Zhu
Suqin Zhu
RLRongcheng Lin
Rongcheng Lin
WCWanghai Cai
Wanghai Cai
HLHongxiang Lin
Hongxiang Lin
YWYongbao Wei
Yongbao Wei
LINC00887 has been mentioned in several articles regarding its involvement in various cancers like nasopharyngeal carcinoma, lung cancer and glioma. However, the mechanism of LINC00887 in the malignant progression of clear cell renal cell carcinoma (ccRCC) is still unclear. The topic of our study is mainly centered on exploring how LINC00887 exactly affects ccRCC malignant progression. The bioinformatics method predicted the downstream TF and target genes of LINC00887 by the "LncRNA-transcription factor (TF)-Gene" triplet model. RNA immunoprecipitation, chromatin immunoprecipitation analysis, and Dual-luciferase reporter assay determined the regulatory relationship between LINC00887 and its downstream genes. The LINC00887 expression and its downstream gene expression in ccRCC cells were examined by qRT-PCR and Western blot. The effect of LINC00887-SPI1-CD70 modulation axis on proliferative transfer, cell stemness and T cell chemotaxis of ccRCC cells was examined in cellular and animal experiments. Our research demonstrated an upregulation of LINC00887 in ccRCC, which facilitated tumor growth and stemness in vivo. In addition, LINC00887 could upregulate the CD70 expression by recruiting transcriptional factor SPI1. The results of in vitro experiments illustrated that the LINC00887-SPI1-CD70 regulatory axis facilitated ccRCC malignant progression by promoting cell stemness and hindering T-cell chemotaxis. LINC00887, by recruiting SPI1, activated CD70 transcription, thereby propelling malignant progression and cell stemness and suppressing T cell chemotaxis in ccRCC. Based on our findings, we believed that the LINC00887-SPI1-CD70 regulatory axis had the potential to be a critical breakthrough for treating ccRCC.

15 June 2026 in npj Aging
Verified
Journal Article
Open access
JWJiawen Wang
Jiawen Wang
YCYupeng Chen
Yupeng Chen
LMLingfeng Meng
Lingfeng Meng
RYRuijie Yao
Ruijie Yao
JZJiong Zhang
Jiong Zhang
YZYaoguang Zhang
Yaoguang Zhang
Pelvic floor disorders, including pelvic organ prolapse and urinary incontinence, represent a common health burden with substantial clinical comorbidity, but their shared genetic architecture remains incompletely understood. We performed a multi-trait genomic analysis of six pelvic-floor-related phenotypes using publicly available GWAS summary statistics from FinnGen R12 and the GWAS Catalog, with Pan-UKBB summary statistics used only for cross-ancestry validation. Linkage disequilibrium score regression and Genomic Structural Equation Modeling identified two broad latent genetic dimensions: a structural factor related to anatomical prolapse and a functional factor related to urinary and bowel dysfunction. MAGMA gene-based analysis identified 267 significant genes enriched for extracellular matrix organization and urogenital developmental pathways, including WNT4, LOXL1, ESR1, WT1, HNF1B, and FGFR2. An exploratory network-informed machine-learning framework incorporating protein-protein interaction topology improved gene prioritization over a baseline Random Forest model and highlighted biologically plausible hub genes. Cross-ancestry analysis of Pan-UKBB female genital prolapse supported directional portability of European-discovered signals and identified WNT4 as a directionally concordant locus. These findings provide a systems-level map of pelvic-floor-related genetic architecture and prioritize candidate genes for future functional validation.

4 March 2024 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
MHMinxiong Hu
Minxiong Hu
YWYangbiao Wu
Yangbiao Wu
XXXiao Xu
Xiao Xu
WCWenchao Cai
Wenchao Cai
JLJiangui Lin
Jiangui Lin
JWJinfeng Wu
Jinfeng Wu
Objectives: The modified three-level technique for retroperitoneal laparoscopic adrenalectomy (RLA) has proven beneficial in the treatment of adrenal lesions in patients with BMI≥25 Kg/m2. This paper aims to summarize our institution’s seven-year experience using this technique for all patients with Adrenal Lesions ≤ 6cm.Patients and methods: Between January 2016 and December 2022. The patients underwent laparoscopic adrenal surgery were categorized into Zhang’s technique (ZT) (Three-level Technique) group and modified technique (MT) group. The fundamental characteristics and perioperative data were analyzed, with statistical significance set at p0.05). The MT group demonstrated superior outcomes compared to the ZT group in terms of operative time, estimated blood loss, drainage volume, diet recovery time, complication rates, and postoperative hospitalization duration (p<0.05). 17 (4.34%) in the ZT group required unplanned adrenalectomy, while there was none in MT group (P<0.05).Conclusion: MT retroperitoneal laparoscopic adrenalectomy has demonstrated its benefits in the treatment of adrenal lesions across all patients with adrenal lesions ≤ 6cm, serving as a valuable point of reference for the surgical management of adrenal diseases.Patient summary: We have made modifications to the classic retroperitoneal laparoscopic adrenalectomy and achieved superior surgical outcomes, resulting in a procedure known as modified retroperitoneal laparoscopic adrenalectomy. This technique is suitable for both obese individuals and the general population with adrenal lesions ≤ 6cm.

21 October 2025 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
JWJiawen Wang
Jiawen Wang
JWJinfu Wang
Jinfu Wang
HLHan Li
Han Li
RWRuo Wang
Ruo Wang
YCYifan Chen
Yifan Chen
JWJinfeng Wu
Jinfeng Wu

14 September 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
YWYongbao Wei
Yongbao Wei
HHHuaishan Hong
Huaishan Hong
DZDewen Zhong
Dewen Zhong
RZRuochen Zhang
Ruochen Zhang
ZGZhixuan Guo
Zhixuan Guo
YZYi Zhang
Yi Zhang
Upper tract urothelial carcinoma (UTUC) carries a high risk of postoperative recurrence; however, the decline in renal function following radical nephroureterectomy often limits the use of cisplatin-based chemotherapy. While the combination of disitamab vedotin and PD-1 inhibitors has demonstrated antitumor activity in advanced urothelial carcinoma, evidence regarding its use as postoperative adjuvant therapy remains limited. This study retrospectively identified patients with UTUC who underwent radical resection with R0 margins and had no distant metastasis prior to treatment, and who subsequently received disitamab vedotin combined with a PD-1 inhibitor due to unsuitability for or refusal of platinum-based chemotherapy. A total of seven patients were included; all were male, with a median age of 65 years. Pathological analysis confirmed pure urothelial carcinoma without histological variants in all cases. Four patients exhibited high-risk features (≥pT3 stage or lymph node positivity); all cases showed HER2 expression of IHC 2+ or 3+ and PD-L1 expression <1%. All patients completed four cycles of the combination therapy. With a median follow-up of 22.3 months, three recurrences and two deaths occurred, including three cases of local recurrence. The 12-month postoperative recurrence-free survival (RFS) rate was 71.4%, and the median RFS had not yet been reached. Treatment-related adverse events (TRAEs) of any grade and Grade ≥3 TRAEs occurred in four and two patients, respectively; no Grade 4–5 adverse events or treatment-related deaths were observed. These results provided a preliminary description of the practical feasibility and observed safety of this regimen in a specific cohort of postoperative UTUC patients; however, given the very small sample size and the lack of a control group, no conclusions regarding therapeutic efficacy could be drawn, and further prospective studies are required for evaluation.